| Company Name: | Dynavax Technologies Corporation | | Ticker Symbol: | DVAX | | | WWW Address: | www.dynavax.com |
| CEO: | Eddie Gray | | No. of Employees: | 167 |
| Common Issue Type: | CS | | Business Description: | Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Other [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 2.55 |  0.02 | 2.54 | 2.58 | 2.52 | 2.56 | 2.50 | 516283 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 466.4 | 182.9 | 2.95 | -0.41 | 0.00 | 0.0 | 0.0 | 5.10 - 1.74 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 2.54 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 466.4 | mil |
| Latest Shares Outstanding | 182.9 | mil |
| Earnings pS (EPS) | -0.41 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 58,168 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 121.6 | mil |
| Float as % of Shares Outstanding | 66.5 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 329.90 | % |
| Research & Devlopment (R&D) as % of Revenue | 538.70 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.1 | % |
| Return on Assets (ROA) | -75.9 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -92.7 | % |
| Current Ratio | 6.3 | |
| Leverage Ratio (Assets/Equity) | 1.2 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 0.50 | $ |
| Cash pS | 0.14 | $ |
| Book-Value pS | 0.54 | $ |
| Tangible Book-Value pS | 0.52 | $ |
| Cash Flow pS | -0.49 | $ |
| Free Cash Flow pS | -0.31 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 4.74 | |
| Price/Tangible Book Ratio | 4.86 | |
| Price/Cash Flow | -5.2 | |
| Price/Free Cash Flow | -8.1 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 1.2 | 102 | 17,282 | 66,063 |
| 4 Weeks | 2.59 | 2.17 | 2.40 | 5.8 | 102 | 14,471 | 289,418 |
| 13 Weeks | 2.59 | 1.74 | 2.97 | -14.5 | 79 | 24,995 | 1,599,656 |
| 26 Weeks | 3.39 | 1.74 | 2.76 | -8.0 | 79 | 26,772 | 3,346,516 |
| 52 Weeks | 5.10 | 1.74 | 3.64 | -30.2 | 56 | 25,480 | 6,344,538 |
| YTD | 3.39 | 1.74 | - | -10.9 | 77 | 26,263 | 2,626,278 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 2.52 | 2.48 | 2.33 | 2.74 | 3.20 | 2.95 | 2.58 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -17.26 | 44.1 | -28.66 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -12.86 | NA | 104.48 |
| R&D | -0.84 | NA | 4.95 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -11.3 | -11.3 | -55.1 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.00 | 0.00 | -0.02 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 78.12 |
| Current Ratio | 6.7 |
| Quick Ratio (Acid Test) | 6.6 |
| Liquidity Ratio (Cash) | 6.58 |
| Receivables Turnover | 1.8 |
| Average Collection Period | 200 |
| Working Capital/Equity | 95.1 |
| Working Capital pS | 0.60 |
| Cash-Flow pS | -0.37 |
| Free Cash-Flow pS | -0.26 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 9.86 |
| Financial Leverage Ratio (Assets/Equity) | 1.2 |
| Debt Ratio | 17.8 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 5.1 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 1.95 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 3.24 |
| Tobin's Q Ratio | 3.32 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -5.39 |
| Enterprise Value (EV)/Free Cash Flow | -7.47 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 4.86 |
| Price/Book Ratio - LTM | 4.74 |
| Price/Cash Flow Ratio | -5.2 |
| Price/Free Cash Flow Ratio - LTM | -8.1 |
| Price/Sales Ratio | 49.16 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.10 |
| Tangible Book Value pS - LTM | 0.52 |
| Book Value pS - LTM | 0.54 |
| Capital Invested pS | 0.63 |
| Cash pS - LTM | 0.14 |
| Cash Flow pS - LTM | -0.49 |
| Free Cash Flow pS - LTM | -0.31 |
| Earnings pS (EPS) | -0.41 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -481.16 |
| Free Cash Flow Margin 5YEAR AVG | -212.36 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | -75.8 |
| Equity Productivity | 0.08 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.08 |
| Return on Capital Invested (ROCI) | -60.9 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -32.7 |
| Assets Productivity | 0.10 |
| Return on Assets (ROA) | -50.1 |
| Return on Assets (ROA) - 5YEAR AVRG. | -20.1 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 37 |
| Revenue per Employee | 58,168 |
| Net Income per Employee | -418,856 |
| Average Collection Period | 37 |
| Receivables Turnover | 1.8 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 22.30 |
| Assets/Revenue | 10.00 |
| Net Working Capital Turnover | 0.09 |
| Fixed Assets Turnover | 0.84 |
| Total Assets Turnover | 0.1 |
| Revenue per $ Cash | 1.28 |
| Revenue per $ Plant | 1.22 |
| Revenue per $ Common Equity | 0.08 |
| Revenue per $ Capital Invested | 0.08 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 289.9 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 70.7 |
| Research & Devlopment (R&D) as % of Revenue | 505.9 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 505.9 |
|
|  
|
| |
 |  |
